Navigation Links
ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
Date:8/30/2007

FREMONT, Calif., Aug. 30 /PRNewswire/ -- ARYx Therapeutics, Inc. announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for a proposed initial public offering of shares of its common stock. All of the shares in the proposed offering will be sold by ARYx Therapeutics.

The underwriters of the offering will be Morgan Stanley & Co. Incorporated acting as sole book runner and lead manager and CIBC World Markets Corp., Jefferies & Company, Inc. and Leerink Swann & Co., Inc. acting as co-managers. The number of shares to be offered and the price range for the offering have not yet been determined.

The offering will be made only by means of a prospectus. When available, a copy of the preliminary prospectus relating to the offering may be obtained from Morgan Stanley & Co. Incorporated by emailing prospectus@morganstanley.com or by contacting the prospectus department at 180 Varick Street, New York, NY 10014 Attn: Prospectus Department.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates designed to eliminate known safety issues associated with well-established, commercially successful drugs. ARYx uses its RetroMetabolic Drug Design(TM) technology to design structurally unique molecules that retain the efficacy of these original drugs but are metabolized through a potentially safer pathway to avoid specific adverse side effects associated with these compounds. ARYx currently has three products in Phase 2 clinical trials: ATI-7505 for the treatment of various gastrointestinal disorders, ATI-5923 for the treatment of patients at risk for the formation of dangerous blood clots, and ATI-2042 for the treatment of atrial fibrillation.


'/>"/>
SOURCE ARYx Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
2. PCR Polymerases Application Profiles
3. RNAlater Preserves Bacterial Gene Expression Profiles for Array Analysis
4. Obtaining a contour map from multifiles or 3D data in DataMax
5. Successful stabilization of gene expression profiles
6. Madison biotech NimbleGen files for IPO; one of states best-funded firms
7. Third Wave files countersuit vs. Digene in patent case
8. TomoTherapy files registration statement for IPO
9. Merge files financial reports by market opening
10. The Why Files celebrates decade of science exploration
11. Third Wave files patent suits against Digene, Chiron and Bayer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Westport, CT (PRWEB) , ... September 20, 2017 , ... ... 2nd annual multi-city Fueling the Growth pitch competition to uncover the top technology-driven, ... Growth will be an integral part of each city’s entrepreneurial events going on that ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... molecular manufacturing and other transformative technologies, announced the winners for the 2017 Foresight ... other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 and named in ...
(Date:9/19/2017)... ... September 19, 2017 , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman ... Riordan’s new book "Stem Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan ... bonded over an interest in the potential of stem cell therapy and a fast friendship ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ in ... analysis to isolate single cells and provide visual documentation of monoclonality for use ...
Breaking Biology Technology:
(Date:8/15/2017)...   ivWatch LLC , a medical device company focused on ... receipt of its ISO 13485 Certification, the global standard for medical ... Standardization (ISO®). ... Continuous Monitoring device for the early detection of IV infiltrations. ... "This is an important milestone for ivWatch, as ...
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/19/2017)... The global military biometrics market ... by the presence of several large global players. The ... major players - 3M Cogent, NEC Corporation, M2SYS Technology, ... 61% of the global military biometric market in 2016. ... military biometrics market boast global presence, which has catapulted ...
Breaking Biology News(10 mins):